Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer

Radiation Oncology

Volumn 5, Issue 1, 2010, Pages

  Kitayama, Joji ^a   Yasuda, Koji ^a   Kawai, Kazushige ^a   Sunami, Eiji ^a   Nagawa, Hirokazu ^a  

^a THE UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; FLUOROURACIL; FOLINIC ACID; HEMOGLOBIN; UFT; ANTINEOPLASTIC AGENT; OXONIC ACID; S 1 (COMBINATION); TEGAFUR; UFT(R) DRUG; URACIL;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; PREOPERATIVE TREATMENT; RECTUM CANCER; THROMBOCYTE COUNT; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; ADJUVANT CHEMOTHERAPY; BLOOD; CANCER STAGING; DRUG COMBINATION; FOLLOW UP; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RECTUM TUMOR; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OXONIC ACID; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 77953013173     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-5-47     Document Type: Article

References (24)

1. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351(17):1731-1740. 10.1056/NEJMoa040694, 15496622.
2. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006, 355(11):1114-1123. 10.1056/NEJMoa060829, 16971718.
3. Ortholan C, Francois E, Thomas O, Benchimol D, Baulieux J, Bosset JF, Gerard JP. Role of radiotherapy with surgery for T3 and resectable T4 rectal cancer: evidence from randomized trials. Dis Colon Rectum 2006, 49(3):302-310. 10.1007/s10350-005-0263-x, 16456638.
4. Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, Eng C, Krishnan S, Janjan NA, Crane CH. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 2007, 109(9):1750-1755. 10.1002/cncr.22625, 17387743.
5. Park HC, Janjan NA, Mendoza TR, Lin EH, Vadhan-Raj S, Hundal M, Zhang Y, Delclos ME, Crane CH, Das P, Wang XS, Cleeland CS, Krishnan S. Temporal Patterns of Fatigue Predict Pathologic Response in Patients Treated with Preoperative Chemoradiation Therapy for Rectal Cancer. Int J Radiat Oncol Biol Phys 2009,
6. Kremser C, Trieb T, Rudisch A, Judmaier W, de Vries A. Dynamic T(1) mapping predicts outcome of chemoradiation therapy in primary rectal carcinoma: sequence implementation and data analysis. J Magn Reson Imaging 2007, 26(3):662-671. 10.1002/jmri.21034, 17729365.
7. Konski A, Li T, Sigurdson E, Cohen SJ, Small W, Spies S, Yu JQ, Wahl A, Stryker S, Meropol NJ. Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys 2009, 74(1):55-59.
8. Jiang SM, Wang RB, Yu JM, Zhu KL, Mu DB, Xu ZF. Correlation of VEGF and Ki67 expression with sensitivity to neoadjuvant chemoradiation in rectal adenocarcinoma. Zhonghua Zhong Liu Za Zhi 2008, 30(8):602-605.
9. Kikuchi M, Mikami T, Sato T, Tokuyama W, Araki K, Watanabe M, Saigenji K, Okayasu I. High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. Br J Cancer 2009, 101(1):116-123. 10.1038/sj.bjc.6605105, 19491899.
10. Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2009, 74(3):673-688.
11. Stjernsward J, Jondal M, Vanky F, Wigzell H, Sealy R. Lymphopenia and change in distribution of human B and T lymphocytes in peripheral blood induced by irradiation for mammary carcinoma. Lancet 1972, 1(7765):1352-1356. 10.1016/S0140-6736(72)91091-4, 4113562.
12. Stratton JA, Byfield PE, Byfield JE, Small RC, Benfield J, Pilch Y. A comparison of the acute effects of radiation therapy, including or excluding the thymus, on the lymphocyte subpopulations of cancer patients. J Clin Invest 1975, 56(1):88-97. 10.1172/JCI108084, 436559, 1095613.
13. O'Toole C, Unsgaard B. Clinical status and rate of recovery of blood lymphocyte levels after radiotherapy for bladder cancer. Cancer Res 1979, 39(3):840-843.
14. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 2004, 10(11):3755-3762. 10.1158/1078-0432.CCR-04-0054, 15173082.
15. Barcellos-Hoff MH, Park C, Wright EG. Radiation and the microenvironment - tumorigenesis and therapy. Nat Rev Cancer 2005, 5(11):867-875. 10.1038/nrc1735, 16327765.
16. Prise KM, Schettino G, Folkard M, Held KD. New insights on cell death from radiation exposure. Lancet Oncol 2005, 6(7):520-528. 10.1016/S1470-2045(05)70246-1, 15992701.
17. Stone HB, Peters LJ, Milas L. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst 1979, 63(5):1229-1235.
18. Demaria S, Formenti SC. Sensors of ionizing radiation effects on the immunological microenvironment of cancer. Int J Radiat Biol 2007, 83(11-12):819-825. 10.1080/09553000701481816, 17852561.
19. Lorimore SA, Coates PJ, Scobie GE, Milne G, Wright EG. Inflammatory-type responses after exposure to ionizing radiation in vivo: a mechanism for radiation-induced bystander effects?. Oncogene 2001, 20(48):7085-7095. 10.1038/sj.onc.1204903, 11704832.
20. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13(9):1050-1059. 10.1038/nm1622, 17704786.
21. Nesslinger NJ, Sahota RA, Stone B, Johnson K, Chima N, King C, Rasmussen D, Bishop D, Rennie PS, Gleave M, Blood P, Pai H, Ludgate C, Nelson BH. Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res 2007, 13(5):1493-1502. 10.1158/1078-0432.CCR-06-1772, 17332294.
22. Schaue D, Comin-Anduix B, Ribas A, Zhang L, Goodglick L, Sayre JW, Debucquoy A, Haustermans K, McBride WH. T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res 2008, 14(15):4883-4890. 10.1158/1078-0432.CCR-07-4462, 2748652, 18676762.
23. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009, 69(4):1553-1560. 10.1158/0008-5472.CAN-08-1921, 19201693.
24. Muller I, Munder M, Kropf P, Hansch GM. Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms?. Trends Immunol 2009, 30(11):522-530. 10.1016/j.it.2009.07.007, 19775938.